Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma.

INTRODUCTION: Chimeric antigen receptor (CAR) T-cell therapies have rapidly become an integral part of the treatment landscape for relapsed or refractory lymphomas. While early clinical trials demonstrated impressive response rates in patients with m…

Preview only. Read the full abstract at the source